All News

Looking forward to “What the fact” – how to differentiate from misinformation versus actual information in social media @DoctorYasmin @DrDavidKarp #ACR21 @RheumNow https://t.co/Wqh29NWNmq
swethaann23 swethaann23 ( View Tweet)
A quick recap slide on VEXAS syndrome presentation. #ACR21 @RheumNow @petercgrayson https://t.co/4x8hBEFWg2
swethaann23 swethaann23 ( View Tweet)
Avacopan (C5a inhibitor) is a new promising therapy for ANCA vasculitis. US FDA approved in Oct 2021 #ACR21 @rheumnow https://t.co/tWvKzHOT5V
swethaann23 swethaann23 ( View Tweet)
Findings: 1. 21% of the patients in the Ankylosing Spondylitis Registry of Ireland (ASRI) were unemployed which is higher than their national average. 2. Stong predictors of unemployment were - Male sex and worse disease activity outcome measures(BASMI and ASQoL) #ACR21 @RheumNow

swethaann23 swethaann23 ( View Tweet)

#ACR21 @RheumNow Abst#0359 by Garrido-Cumbrera et al. has mapped out the journey from symptom onset to diagnosis of axSpA across 13 European countries.

swethaann23 swethaann23 ( View Tweet)

#ACR21 @RheumNow Abst#0364 by Wetterslev et al. sought to identify axSpA characteristics of patients tapered off TNFI and showed clinical and radiographic improvement. 🔽52% were tapered off ⭐️The highest predictor of success is a low physician global VAS score

swethaann23 swethaann23 ( View Tweet)

Our recap of Day 2 of #ACR21 is now available on YouTube and the @RheumNow website, where you can find lots more videos, interviews and articles from the conference! https://t.co/BxBXipxzif @drdavidliew @doctorRBC @swethaann23 @MeralElRamahiMD

Mrinalini Dey DrMiniDey ( View Tweet)

⭐️AxSpA pts with decrease in oral microbial diversity ⭐️Immune response to oral/fecal microbes altered in AxSpA pts. ⭐️HLA-B27 associated ⬆️IgA coated microbes, may contribute to development of AxSpA Abs#0052 https://t.co/NQgm0lpYJj #ACR21 @RheumNow

Links:

Robert B Chao, MD doctorRBC ( View Tweet)

Dr Preger report 9 novel aminoacyl tRNA synthetases in IIM patients. May these allow us to spare more patients biopsy? Abstr#0001 #ACR21 @RheumNow https://t.co/ikNXCEOeuj
Richard Conway RichardPAConway ( View Tweet)
Meta-analysis from @rheum_covid with @HsiehEvelyn shows that people with rheumatic disease are at⬆️risk of SARS-CoV-2 infection and⬆️mortality from COVID-19. Abstr#0086 #ACR21 @RheumNow #ACRBest https://t.co/B7tWs02gfc
Richard Conway RichardPAConway ( View Tweet)
Dr Doliner @zach_wallace_md on ILD in AAV. ILD in 13% - of which 76% fibrotic. UIP most common. Most MPO+, but also rarely seen with PR3+. 47% ⬆️ risk of death. Abstr#0430 #ACR21 @RheumNow https://t.co/6MnxqW92bz
Richard Conway RichardPAConway ( View Tweet)
Completely new one for me, Dr Taniguchi presenting on using ear ultrasound to diagnose and monitor disease activity in relapsing polychondritis. Appears useful, I suspect in clinical practice more so for diagnosis. Abstr#0169 #ACR21 @RheumNow https://t.co/PLJtkYkP3A
Richard Conway RichardPAConway ( View Tweet)
Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆️ mortality, aHR 2.16 . Abstr#0085 #ACR21 @RheumNow https://t.co/wyfEBWurRi
Richard Conway RichardPAConway ( View Tweet)
Dr McDermott @jeffsparks on risk factors for RA-bronchiectasis. Seropositivity, older age at RA onset, and lower BMI⬆️risk. Abstr#0288 #ACR21 @RheumNow https://t.co/7d2ZVWLzn6
Richard Conway RichardPAConway ( View Tweet)
Dr O'Brien on co-existent AAV and RA. Not something I'm used to seeing, but maybe we need to think about it more? 25 cases with RA+AAV, 52 with RA + ANCA but no AAV, not sure what the denominator is here though. Abstr#0428 #ACR21 @RheumNow @profgayecunnane https://t.co/fN3BRpc7UJ
Richard Conway RichardPAConway ( View Tweet)
Dr Adachi presents ⬆️BMD gain with denosumab than risedronate in RA. Non-significant reduction in fractures (very small numbers) Interesting, but need to see fracture benefit in larger study to justify dmab as first line Abstr#0445 #ACR21 @RheumNow https://t.co/GgaS9JZGzb
Richard Conway RichardPAConway ( View Tweet)
Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg
Richard Conway RichardPAConway ( View Tweet)
Diabetes puts you at risk of cardiovascular disease, right? What about RA? Look at this graph and compare the pair. "already it was impossible to say which was which” - George Orwell, Animal Farm #ACR21 ABST0287 @RheumNow https://t.co/r0yaeC530l https://t.co/mKJhoyJ2Cn

Links:

David Liew drdavidliew ( View Tweet)
Year 2 f/u on PsA, axSpA, or RA using CT-P13, an infliximab (IFX) biosimilar. Pts either naive to IFX or switched from IFX: 💠IFX-naive: improved disease activity 💠IFX-switched: maintained stable disease 💠No new safety concerns https://t.co/VGBicnq15w #ACR21 Abst#0817 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

Small but important study of LN Class III, IV, and/or V with 6/18 pts considered complete responders by UProt (<500mg/g) continued to⬇️in renal fxn over 5 yrs. Bottom line: even dramatic ⬇️UProt does not tell the whole story. https://t.co/51x4DlXkJC #ACR21 Abst#1284 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

×